Depakote Behavioral Side Effects: Navigating Mood Changes and Mental Health Impacts
[Entertaining phrasing!] Explore Depakote's behavioral side effects, from mood swings to cognitive changes. Learn strategies to manage these impacts and make informed treatment decisions.
Central nervous system (CNS) depressants used to manage symptoms of psychosis and anxiety disorders include antipsychotics and anxiolytics, which may cause psychosis. Antipsychotics are also…
All antipsychotics block the D2 (dopaminergic) receptor, which in turn promotes the presence of EPS, resulting in drug-induced pseudoparkinsonism in varying degrees.
All antipsychotics block the D2 (dopaminergic) receptor, which in turn promotes the presence of EPS, resulting in drug-induced pseudoparkinsonism in varying degrees
they block the serotonin receptor.
Pseudoparkinsonism, which resembles symptoms of parkinsonism, is a major side effect of typical antipsychotic drugs.
stooped posture, masklike facies, rigidity, tremors at rest, shuffling gait, pill-rolling motions of the hands
Oral Fenbendazole for Cancer Therapy in Humans and Animals
Fenbendazole is a benzimidazole anthelmintic agent commonly used to treat animal parasitic infections. In humans, other benzimidazoles, such as mebendazole and albendazole, are used as antiparasitic agents. Since fenbendazole is not currently approved by the FDA or EMA, its pharmacokinetics and safety in humans have yet to be well-documented in medical literature. Despite this, insights can be drawn from existing in vitro and in vivo animal studies on its pharmacokinetics. Given the low cost of fenbendazole, its high safety profile, accessibility, and unique anti-proliferative activities, fenbendazole would be the preferred benzimidazole compound to treat cancer. To ensure patient safety in the repurposing use of fenbendazole, it is crucial to perform clinical trials to assess its potential anticancer effects, optimal doses, therapeutic regimen, and tolerance profiles. This review focuses on the pharmacokinetics of orally administered fenbendazole and its promising anticancer biological activities, such as inhibiting glycolysis, down-regulating glucose uptake, inducing oxidative stress, and enhancing apoptosis in published experimental studies. Additionally, we evaluated the toxicity profile of fenbendazole and discussed possibilities for improving the bioavailability of the drug, enhancing its efficacy, and reducing potential toxicity.
Cholinesterase Inhibitors: Alzheimer's Uses, Side Effects
Cholinesterase inhibitors are drugs that prevent the breakdown of acetylcholine, and blocks the action of acetylcholinesterase in the body. Researchers believe that decreased levels of acetylcholine in the brain causes Alzheimer's disease symptoms. Common side effects of cholinesterase inhibitors are insomnia, abnormal dreams, weight loss, headache, nausea, vomiting, diarrhea, confusion, and fatigue.
~Venlafaxine and ODV have no significant affinity for muscarinic,
~Aggression may occur in some patients who have received antidepressants, including venlafaxine treatment, dose reduction, or discontinuation
~aggression have been observed in patients during changes in venlafaxine dosing regimen, including during discontinuation
~Discontinuation.. symptoms include aggression, agitation,
Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease
Cholinergic transmission at muscarinic acetylcholine receptors (mAChR) has been implicated in higher brain functions such as learning and memory, and loss of synapses may contribute to the symptoms of Alzheimer disease. A heterogeneous family of ...
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
Cognitive impairment is a core symptom of schizophrenia and a major determinant of poor long-term functional outcomes. Despite considerable efforts, we do not yet have any approved pharmacological treatments for cognitive impairment associated with ...
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM
The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid
of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium
is a peripherally restri...
Dementia with Lewy bodies (DLB) is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic bodily functions. Memory loss is not always an early symptom. The disease worsens over time and is usually diagnosed when cognitive impairment interferes with normal daily functioning. Together with Parkinson's disease dementia, DLB is one of the two Lewy body dementias. It is a common form of dementia, but the prevalence is not known accurately and many diagnoses are missed. The disease was first described on autopsy by Kenji Kosaka in 1976, and he named the condition several years later.
Five Things You Didn't Know About Antibiotics and Your Brain
Yes, antibiotics are miracle drugs, but they have some quirks. Among them are unexpected interactions with the brain. Here are five surprising connections.
Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection
"patients in treatment of RCDI and regularly encountered post-FMT re-infections with C. difficile following uncomplicated UTI treatment with all commonly used oral antibiotics, including quinolones, penicillins, cephalosporins, macrolides, sulfamethoxazole/trimethoprim, nitrofurantoin and fosfomycin"
patients in treatment of RCDI and regularly encountered post-FMT re-infections with C. difficile following uncomplicated UTI treatment with all commonly used oral antibiotics, including quinolones, penicillins, cephalosporins, macrolides, sulfamethoxazole/trimethoprim, nitrofurantoin and fosfomycin
she had not had a UTI episode for over 3 months
regimen of methenamine hippurate and ascorbic acid
positive test for C. difficile
while on vancomycin
discharged after 3 days of treatment with amikacin